BOSTON SCIENTIFIC CORP (BSX) Fundamental Analysis & Valuation

NYSE:BSX • US1011371077

71.37 USD
+0.02 (+0.03%)
Last: Mar 9, 2026, 12:14 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BSX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Taking everything into account, BSX scores 7 out of 10 in our fundamental rating. BSX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. BSX has an excellent profitability rating, but there are some minor concerns on its financial health. BSX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, BSX could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

9

1. BSX Profitability Analysis

1.1 Basic Checks

  • In the past year BSX was profitable.
  • BSX had a positive operating cash flow in the past year.
  • BSX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BSX had a positive operating cash flow.
BSX Yearly Net Income VS EBIT VS OCF VS FCFBSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a Return On Assets of 6.64%. This is amongst the best in the industry. BSX outperforms 84.78% of its industry peers.
  • The Return On Equity of BSX (11.96%) is better than 86.96% of its industry peers.
  • BSX has a better Return On Invested Capital (8.70%) than 85.33% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BSX is in line with the industry average of 9.15%.
  • The 3 year average ROIC (7.70%) for BSX is below the current ROIC(8.70%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX Yearly ROA, ROE, ROICBSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • BSX's Profit Margin of 14.44% is amongst the best of the industry. BSX outperforms 90.22% of its industry peers.
  • In the last couple of years the Profit Margin of BSX has grown nicely.
  • The Operating Margin of BSX (19.92%) is better than 91.85% of its industry peers.
  • BSX's Operating Margin has improved in the last couple of years.
  • BSX's Gross Margin of 69.01% is fine compared to the rest of the industry. BSX outperforms 76.63% of its industry peers.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX Yearly Profit, Operating, Gross MarginsBSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BSX Health Analysis

2.1 Basic Checks

  • BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, BSX has more shares outstanding
  • BSX has more shares outstanding than it did 5 years ago.
  • BSX has a better debt/assets ratio than last year.
BSX Yearly Shares OutstandingBSX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX Yearly Total Debt VS Total AssetsBSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • BSX has an Altman-Z score of 4.30. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BSX (4.30) is better than 75.54% of its industry peers.
  • The Debt to FCF ratio of BSX is 3.13, which is a good value as it means it would take BSX, 3.13 years of fcf income to pay off all of its debts.
  • BSX has a Debt to FCF ratio of 3.13. This is amongst the best in the industry. BSX outperforms 82.61% of its industry peers.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.46, BSX is in line with its industry, outperforming 45.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 4.3
ROIC/WACC0.9
WACC9.63%
BSX Yearly LT Debt VS Equity VS FCFBSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 1.62 indicates that BSX should not have too much problems paying its short term obligations.
  • BSX's Current ratio of 1.62 is on the low side compared to the rest of the industry. BSX is outperformed by 72.83% of its industry peers.
  • BSX has a Quick Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Quick ratio of 1.08. This is in the lower half of the industry: BSX underperforms 75.54% of its industry peers.
  • The current and quick ratio evaluation for BSX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX Yearly Current Assets VS Current LiabilitesBSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • Measured over the past years, BSX shows a very strong growth in Earnings Per Share. The EPS has been growing by 26.01% on average per year.
  • The Revenue has grown by 19.88% in the past year. This is quite good.
  • Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 15.16% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.13% on average per year.
  • The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue Next Year10.94%
Revenue Next 2Y10.71%
Revenue Next 3Y10.55%
Revenue Next 5Y10.46%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX Yearly Revenue VS EstimatesBSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX Yearly EPS VS EstimatesBSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. BSX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.40, the valuation of BSX can be described as rather expensive.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than 77.17% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BSX to the average of the S&P500 Index (26.29), we can say BSX is valued inline with the index average.
  • With a Price/Forward Earnings ratio of 20.41, BSX is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, BSX is valued a bit cheaper than 79.89% of the companies in the same industry.
  • BSX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.60, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.4
Fwd PE 20.41
BSX Price Earnings VS Forward Price EarningsBSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 73.37% of the companies in the same industry are more expensive than BSX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 79.35% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 28.95
EV/EBITDA 21.49
BSX Per share dataBSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has an outstanding profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.6
PEG (5Y)0.9
EPS Next 2Y13.93%
EPS Next 3Y13.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX Dividend Analysis

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

NYSE:BSX (3/9/2026, 12:14:05 PM)

71.37

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.17%
Inst Owner Change2.85%
Ins Owners0.16%
Ins Owner Change2.41%
Market Cap105.91B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts85.5
Price Target107.14 (50.12%)
Short Float %1.8%
Short Ratio1.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-14.64%
PT rev (3m)-16.46%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)0.67%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-0.05%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.44%
Revenue NY rev (3m)-0.43%
Valuation
Industry RankSector Rank
PE 23.4
Fwd PE 20.41
P/S 5.28
P/FCF 28.95
P/OCF 23.36
P/B 4.37
P/tB N/A
EV/EBITDA 21.49
EPS(TTM)3.05
EY4.27%
EPS(NY)3.5
Fwd EY4.9%
FCF(TTM)2.47
FCFY3.45%
OCF(TTM)3.06
OCFY4.28%
SpS13.53
BVpS16.33
TBVpS-0.72
PEG (NY)1.6
PEG (5Y)0.9
Graham Number33.48
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 4.3
F-Score7
WACC9.63%
ROIC/WACC0.9
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.94%
Revenue Next 2Y10.71%
Revenue Next 3Y10.55%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to BSX.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX). This can be considered as Fairly Valued.


How profitable is BOSTON SCIENTIFIC CORP (BSX) stock?

BOSTON SCIENTIFIC CORP (BSX) has a profitability rating of 9 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX) is 23.4 and the Price/Book (PB) ratio is 4.37.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 14.65% in the next year.